AlxMed, a Santa Clara, CA-based early-stage smart cytology company, raised $2.75M in SAFE funding.
The backers were not disclosed.
The company intends to use the funds to further develop its digital cytology platform. Fundraising proceeds will be used to add a Chief Medical Officer to its leadership team and to support validation studies prior to FDA submission.
Led by CEO Samuel Chen, AIxMed helps pathologists digitize cytology samples in minutes and extract clinical insights in seconds to improve patient diagnosis and care. Its first application, AIxURO, is an AI-assisted urine cytology imaging and reporting software package for bladder cancer diagnosis and surveillance based on The Paris System (TPS). The company has recently concluded a pilot study and the results were published in Cancer Cytopathology. It is an RUO application at this time.
The next fundraising series to support commercialization efforts is slated for late 2023.
FinSMEs
27/04/2023